{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=darolutamide&page=3", "query": { "intervention": "darolutamide", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 73, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=darolutamide&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=darolutamide&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T16:11:33.232Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05519449", "title": "Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer", "Metastatic Castration-resistant Prostate Cancer", "Castration Resistant Prostatic Cancer" ], "interventions": [ { "name": "JANX007", "type": "BIOLOGICAL" }, { "name": "Darolutamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Janux Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 272, "start_date": "2022-09-15", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-10-29", "last_synced_at": "2026-11-15T16:11:33.232Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05519449" }, { "nct_id": "NCT07611110", "title": "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Deutenzalutamide", "type": "DRUG" }, { "name": "Radium-223", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 670, "start_date": "2026-05-04", "completion_date": "2030-06-06", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-15T16:11:33.232Z", "location_count": 28, "location_summary": "Dothan, Alabama • Phoenix, Arizona • Duarte, California + 24 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07611110" }, { "nct_id": "NCT03004534", "title": "A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Cancer Female" ], "interventions": [ { "name": "darolutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Translational Research in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 36, "start_date": "2017-09-05", "completion_date": "2019-03-13", "has_results": true, "last_update_posted_date": "2020-04-03", "last_synced_at": "2026-11-15T16:11:33.232Z", "location_count": 5, "location_summary": "Los Angeles, California • Redondo Beach, California • Santa Maria, California + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redondo Beach", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03004534" }, { "nct_id": "NCT07140900", "title": "Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Hormone-sensitive Prostate Cancer (mHSPC)" ], "interventions": [ { "name": "Xaluritamig", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2025-10-07", "completion_date": "2029-10-29", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-15T16:11:33.232Z", "location_count": 8, "location_summary": "San Francisco, California • Boston, Massachusetts • Minneapolis, Minnesota + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07140900" }, { "nct_id": "NCT07244341", "title": "A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Valemetostat", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2025-12-03", "completion_date": "2029-11-30", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-15T16:11:33.232Z", "location_count": 9, "location_summary": "La Jolla, California • Boston, Massachusetts • Newton, Massachusetts + 6 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Newton", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07244341" }, { "nct_id": "NCT04237584", "title": "A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Enzalutamide during Lead-in Period", "type": "DRUG" }, { "name": "Lead-in Enzalutamide followed by Radium-223/Enzalutamide", "type": "DRUG" }, { "name": "Lead-in Enzalutamide followed by Placebo/Enzalutamide", "type": "DRUG" }, { "name": "Darolutamide during Lead-in Period", "type": "DRUG" }, { "name": "Lead-in Darolutamide followed by Radium-223/Darolutamide", "type": "DRUG" }, { "name": "Lead-in Darolutamide followed by Placebo/Darolutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MANA RBM", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 23, "start_date": "2020-06-30", "completion_date": "2022-03-07", "has_results": true, "last_update_posted_date": "2022-10-07", "last_synced_at": "2026-11-15T16:11:33.232Z", "location_count": 1, "location_summary": "Myrtle Beach, South Carolina", "locations": [ { "city": "Myrtle Beach", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04237584" }, { "nct_id": "NCT05362149", "title": "An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Darolutamide (Nubeqa, BAY1841788)", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 870, "start_date": "2022-04-04", "completion_date": "2023-06-30", "has_results": false, "last_update_posted_date": "2024-03-20", "last_synced_at": "2026-11-15T16:11:33.232Z", "location_count": 1, "location_summary": "Whippany, New Jersey", "locations": [ { "city": "Whippany", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05362149" }, { "nct_id": "NCT06190899", "title": "Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "mCRPC (Metastatic Castration-resistant Prostate Cancer)", "Genital Diseases, Male", "Urogenital Diseases, Male", "Prostatic Disease", "Prostatic Neoplasms, Castration-Resistant", "Prostate Cancer" ], "interventions": [ { "name": "Gedatolisib", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celcuity Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 54, "start_date": "2024-01-01", "completion_date": "2030-01", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-11-15T16:11:33.232Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06190899" }, { "nct_id": "NCT04484818", "title": "Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Carcinoma" ], "interventions": [ { "name": "Darolutamide", "type": "DRUG" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Leuprolide Acetate", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Triptorelin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 27, "start_date": "2021-03-01", "completion_date": "2028-05-31", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-11-15T16:11:33.232Z", "location_count": 115, "location_summary": "Duarte, California • Los Angeles, California • Palo Alto, California + 88 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04484818" }, { "nct_id": "NCT05612880", "title": "Physical Function During ARSI Treatment", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Advanced Prostate Carcinoma" ], "interventions": [ { "name": "androgen receptor signaling inhibitors", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 24, "start_date": "2022-10-13", "completion_date": "2024-11-06", "has_results": false, "last_update_posted_date": "2025-01-09", "last_synced_at": "2026-11-15T16:11:33.232Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05612880" } ] }